Clorox (NYSE:CLX) Price Target Lowered to $125.00 at Bank of America

Key Points

• Bank of America has lowered its price target for Clorox (NYSE:CLX) from $135.00 to $125.00, maintaining a "neutral" rating on the stock, which suggests a potential upside of 4.45% from its previous close.
• Other analysts have also adjusted their ratings, with Zacks Research upgrading to "hold" while Barclays set their target at $112.00 with an "underweight" rating.
• Despite the mixed ratings, Clorox reported better-than-expected earnings of $2.87 per share, exceeding estimates and indicating a revenue increase of 4.5% compared to the previous year.

Clorox (NYSE:CLX - Get Free Report) had its price target lowered by equities research analysts at Bank of America from $135.00 to $125.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Bank of America's target price would indicate a potential upside of 4.45% from the company's previous close.

A number of other brokerages have also recently commented on CLX. Zacks Research upgraded shares of Clorox from a "strong sell" rating to a "hold" rating in a research note on Monday, September 29th. Barclays dropped their price objective on shares of Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Tuesday, September 30th. JPMorgan Chase & Co. increased their price objective on shares of Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a research report on Monday, September 8th. UBS Group dropped their price objective on shares of Clorox from $134.00 to $128.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Morgan Stanley dropped their price objective on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $132.92.

Clorox Trading Down 0.7%

NYSE:CLX traded down $0.81 during trading hours on Wednesday, hitting $119.68. The stock had a trading volume of 1,033,909 shares, compared to its average volume of 1,685,701. Clorox has a one year low of $116.53 and a one year high of $171.37. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 0.97 and a beta of 0.52. The business's 50 day moving average is $122.51 and its 200-day moving average is $129.17.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm earned $1.82 earnings per share. The firm's revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Sell-side analysts anticipate that Clorox will post 7.15 EPS for the current fiscal year.

Insider Buying and Selling at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.57% of the company's stock.

Institutional Investors Weigh In On Clorox

A number of hedge funds have recently made changes to their positions in CLX. Simplicity Wealth LLC boosted its position in Clorox by 157.3% during the 2nd quarter. Simplicity Wealth LLC now owns 18,316 shares of the company's stock worth $2,199,000 after buying an additional 11,198 shares during the period. Raymond James Financial Inc. boosted its position in Clorox by 15.6% during the 1st quarter. Raymond James Financial Inc. now owns 269,926 shares of the company's stock worth $39,747,000 after buying an additional 36,352 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in Clorox during the 1st quarter worth approximately $247,000. Brown Miller Wealth Management LLC acquired a new stake in Clorox during the 1st quarter worth approximately $399,000. Finally, Roman Butler Fullerton & Co. acquired a new stake in Clorox during the 1st quarter worth approximately $400,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.